11.48 USD
+0.88 (+8.3%)
11.48 USD
0 (0%)
Overall NEO gets a fundamental rating of 3 out of 10. We evaluated NEO against 101 industry peers in the Health Care Providers & Services industry. NEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NEO was profitable.
In the past year NEO had a positive cash flow from operations.
NEO had negative earnings in 4 of the past 5 years.
In multiple years NEO reported negative operating cash flow during the last 5 years.
1.2 Ratios
NEO has a worse Return On Assets (-8.25%) than 71.29% of its industry peers.
Looking at the Return On Equity, with a value of -13.54%, NEO is doing worse than 61.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 43.46%, NEO is doing good in the industry, outperforming 72.28% of the companies in the same industry.
In the last couple of years the Gross Margin of NEO has declined.
The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEO has more shares outstanding
Compared to 5 years ago, NEO has more shares outstanding
NEO has a worse debt/assets ratio than last year.
2.2 Solvency
NEO has an Altman-Z score of 1.77. This is a bad value and indicates that NEO is not financially healthy and even has some risk of bankruptcy.
NEO has a Altman-Z score of 1.77. This is comparable to the rest of the industry: NEO outperforms 41.58% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that NEO is not too dependend on debt financing.
NEO has a better Debt to Equity ratio (0.41) than 64.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.77 |
ROIC/WACCN/A
WACC7.74%
2.3 Liquidity
NEO has a Current Ratio of 3.91. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Current ratio of 3.91. This is amongst the best in the industry. NEO outperforms 90.10% of its industry peers.
NEO has a Quick Ratio of 3.62. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO's Quick ratio of 3.62 is amongst the best of the industry. NEO outperforms 90.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.11% over the past year.
Measured over the past years, NEO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.25% on average per year.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.10%.
The Revenue has been growing by 10.07% on average over the past years. This is quite good.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
3.2 Future
The Earnings Per Share is expected to grow by 45.70% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.43% on average over the next years. This is quite good.
EPS Next Y-12.63%
EPS Next 2Y31.64%
EPS Next 3Y56.98%
EPS Next 5Y45.7%
Revenue Next Year9.42%
Revenue Next 2Y9.63%
Revenue Next 3Y9.49%
Revenue Next 5Y9.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 114.80 indicates a quite expensive valuation of NEO.
NEO's Price/Earnings is on the same level as the industry average.
NEO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.45.
The Price/Forward Earnings ratio is 66.25, which means the current valuation is very expensive for NEO.
NEO's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 34.46. NEO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 114.8 | ||
| Fwd PE | 66.25 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NEO's earnings are expected to grow with 56.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.64%
EPS Next 3Y56.98%
5. Dividend
5.1 Amount
NEO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.48
+0.88 (+8.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.35%
Inst Owner Change1.24%
Ins Owners1.17%
Ins Owner Change1.98%
Market Cap1.48B
Revenue(TTM)709.16M
Net Income(TTM)-113.47M
Analysts71.58
Price Target12.44 (8.36%)
Short Float %5.63%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.29%
Min EPS beat(2)31.6%
Max EPS beat(2)40.97%
EPS beat(4)4
Avg EPS beat(4)51.9%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)207.03%
EPS beat(12)12
Avg EPS beat(12)159.81%
EPS beat(16)16
Avg EPS beat(16)125.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.73%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)1.77%
PT rev (1m)27.2%
PT rev (3m)44.3%
EPS NQ rev (1m)-15.49%
EPS NQ rev (3m)-20.6%
EPS NY rev (1m)-5.02%
EPS NY rev (3m)-5.02%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)-0.33%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 114.8 | ||
| Fwd PE | 66.25 | ||
| P/S | 2.09 | ||
| P/FCF | N/A | ||
| P/OCF | 108.6 | ||
| P/B | 1.77 | ||
| P/tB | 74.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.1
EY0.87%
EPS(NY)0.17
Fwd EY1.51%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.11
OCFY0.92%
SpS5.49
BVpS6.49
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.15% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 | ||
| Altman-Z | 1.77 |
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
EPS Next Y-12.63%
EPS Next 2Y31.64%
EPS Next 3Y56.98%
EPS Next 5Y45.7%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
Revenue Next Year9.42%
Revenue Next 2Y9.63%
Revenue Next 3Y9.49%
Revenue Next 5Y9.43%
EBIT growth 1Y-6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.86%
EBIT Next 3Y41.96%
EBIT Next 5Y28.43%
FCF growth 1Y65.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.31%
OCF growth 3YN/A
OCF growth 5Y-21.37%
NEOGENOMICS INC / NEO FAQ
What is the fundamental rating for NEO stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEO.
What is the valuation status of NEOGENOMICS INC (NEO) stock?
ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.
How profitable is NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a profitability rating of 1 / 10.
What are the PE and PB ratios of NEOGENOMICS INC (NEO) stock?
The Price/Earnings (PE) ratio for NEOGENOMICS INC (NEO) is 114.8 and the Price/Book (PB) ratio is 1.77.
Can you provide the financial health for NEO stock?
The financial health rating of NEOGENOMICS INC (NEO) is 4 / 10.